Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1Other hematologic neoplasm 1Myeloid 1

Conditions

Thrombocythemia, Essential 1Primary Myelofibrosis 1Preleukemia 1Precancerous Conditions 1Neoplasms by Histologic Type 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Diseases 1Bone Marrow Diseases 1

Interventions

fludarabine phosphate 31Cyclophosphamide 27Mycophenolic Acid 22Whole-Body Irradiation 21Tacrolimus 21ruxolitinib 19Peripheral Blood Stem Cell Transplantation 19Busulfan 19Antilymphocyte Serum 16fludarabine 14Melphalan 12Methotrexate 11Cyclosporine 10thymoglobulin 9Cord Blood Stem Cell Transplantation 7Sirolimus 6Radiotherapy 6Etoposide 6Azacitidine 6Stem Cell Transplantation 5Granulocyte Colony-Stimulating Factor 5Cyclosporins 4pomalidomide 3parsaclisib 3Surveys and Questionnaires 3Rituximab 3Prednisone 3Filgrastim 3Cytarabine 311-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Primary Myelofibrosis × CPI-0610 × Clear all
NCT02158858 2026-06-04

A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative Malignancies

Constellation Pharmaceuticals

Phase 1/2 Completed
336 enrolled 61 charts
MyeloidOther hematologic neoplasmOther neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Precancerous Conditions, Preleukemia, Thrombocythemia, Essential, Leukemia, Myeloid, Acute, Myelodysplastic-Myeloproliferative Diseases, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡